Evidence map›Paper›PMID 30018523›Full record

ArticleRadiology and oncology2018

Survival and Stability of Patients with Urothelial Cancer and Spinal Bone Metastases after Palliative Radiotherapy.

Robert Foerster, Katharina Hees, Thomas Bruckner, Tilman Bostel, Ingmar Schlampp, Tanja Sprave, Nils H Nicolay, Juergen Debus, Harald Rief

Open access · goldAbstract read
In one paragraph

Article in Radiology and oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Robert FoersterDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Katharina HeesDepartment of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.
Thomas BrucknerDepartment of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.
Tilman BostelDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Ingmar SchlamppDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Tanja SpraveDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Nils H NicolayDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Juergen DebusDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Harald RiefDepartment of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Heidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the study was to analyze survival and stability of patients with urothelial cell cancer and spinal bone metastases (SBM) after radiotherapy (RT). Furthermore, to assess the effects of RT on bone mineral density (BMD) as a local response in SBM after RT. PATIENTS AND

methodsSurvival of 38 patients with 132 SBM from urothelial cancer, treated from January 2000 to January 2012, was calculated. Stability of irradiated thoracic and lumbar SBM was retrospectively evaluated in computed tomography (CT) scans using the validated Taneichi

resultsAll patients died during follow-up. Overall survival (OS) after 6 months, 1 year and 2 years was 90%, 80% and 40%, respectively. Bone survival (BS) was 85%, 64% and 23% after 6 months, 1 year and 2 years, respectively. Survival from start of RT (RTS) was 42% after 6 months, 18% after 1 year and 5% after 2 years. Only 11% received bisphosphonates. Stability did not improve at 3 or 6 months after RT. BMD increased by 25.0 HU ± 49.7 SD after 3 months (p = 0.001) and by 24.2 HU ± 52.2 SD after 6 months (p = 0.037). Pain relief (> 2 points on the visual analogue scale) was achieved in only 27% of patients.

conclusionsBenefit from palliative RT of painful or unstable SBM is limited in these patients and they should be carefully selected for RT. Shorter fractionation schedules may be preferred and outcome may improve with concomitant bisphosphonates.

Indexed as

bone densitybone metastasesstabilitysurvivalurothelial cancer

Identifiers

PMID30018523
PMCPMC6043884
OpenAlexW2754220751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.